Using a medication to treat headaches after mild brain injuries in military and civilian patients
Official title: Treatment of Acute Post-Traumatic Headache With Erenumab 140 mg, Military Service Members and Civilians With Mild TBI: A Randomized, Double Blind, Placebo Controlled, Multicenter 12-week Duration Study Followed by a 4-week Open-Label Safety Extension
Run by Henry M. Jackson Foundation for the Advancement of Military Medicine · NCT05049057 · Data updated 2026-11-12
This study is testing if a new medication can help people with mild brain injuries and headaches feel better compared to a placebo.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 50 Years |
| Sex | All |
| Enrollment | 404 (estimated) |
| Sponsor | Henry M. Jackson Foundation for the Advancement of Military Medicine Academic / other |
| Drugs / interventions | erenumab |
| Locations | 4 sites (Fort Bragg, North Carolina and 3 other locations) |
| Status | Recruiting |
| Started | July 19, 2022 |
| Main results expected | May 19, 2026 |
| Study ends | May 19, 2027 |
| Registry record updated | February 22, 2024 |
| Trial ID | NCT05049057 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are military service members and civilians aged 18 to 50 who have experienced mild traumatic brain injury and posttraumatic headache within the past week.
✕Probably not a fit
Patients with moderate or severe traumatic brain injuries or chronic headache disorders may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the safety and effectiveness of erenumab, a monoclonal antibody targeting calcitonin gene-related peptide (CGRP), for treating acute posttraumatic headache (PTH) in individuals with mild traumatic brain injury (mTBI). It is a randomized, double-blind, placebo-controlled trial conducted at military treatment facilities across the United States. Participants will receive either erenumab or a placebo to determine the medication's impact on headache relief and overall safety. The study focuses on individuals who have experienced mTBI and PTH within the last week.
Why it matters
Potential benefit: If successful, this treatment could significantly alleviate headache symptoms in patients suffering from posttraumatic headaches following mild traumatic brain injuries.
How similar studies have gone: Other studies have shown promising results with CGRP inhibitors for migraine treatment, suggesting potential success for this novel application in posttraumatic headache.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male or female ≥18 and ≤50 years of age * mTBI from any cause including impact, rotational acceleration, blast, or a combination, has occurred within the prior 7 days * PTH has occurred within the prior 7 days * Able to provide informed consent * Likely to stay in the same geographical area for the duration of study * Has a personal health care provider for standard of care PTH and TBI, including education, diagnostic procedures including neuroimaging and treatment, as deemed clinically indicated by the health care provider Exclusion Criteria: * Sustained a moderate or severe TBI, rather than mTBI, indicated with at least 1 of the following associated with head injury: 1. abnormal structural imaging 2. loss of consciousness for \>30 minutes 3. alteration of consciousness/mental state for \>24 hours 3. post-traumatic amnesia for \>1 day * Participants with ongoing chronic migraine or other chronic daily headache disorders at the time of injury
Where it's running
-
Womack Army Medical Center - Fort Liberty
Fort Bragg, North Carolina, United States Recruiting -
William Beaumont Army Medical Center
El Paso, Texas, United States Recruiting -
University of Pittsburgh Concussion Research Laboratory
Pittsburgh, Pennsylvania, United States Not yet recruiting -
Madigan Army Medical Center
Tacoma, Washington, United States Not yet recruiting
Study contacts
- Principal investigator: David L Brody, MD, PhD — Uniformed Services University of the Health Sciences
- Study coordinator: Amy Guthrie, RN
- Email: amy.guthrie.ctr@usuhs.edu
- Phone: 202-924-2729
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Recovery after mild traumatic brain injury in older adults
This project will follow people 65 and older who had a mild TBI to see how their thinking, physical abilities, mood, and sleep change over the year after injury.
-
TES HT100 screening for intracranial problems after mild head injury or new neurological symptoms
This test checks if the TES HT100 can quickly and safely find intracranial problems in adults who come to the emergency department with mild head injury or new non‑traumatic neurological symptoms.
-
Two online brain-training programs to help emotional health after mild TBI
This study tests two remote brain-training programs to see which better improves emotional health in adults with mild traumatic brain injury and alexithymia.
-
Cognitive behavioral therapy for insomnia in people with mild traumatic brain injury
This study will try cognitive behavioral therapy for insomnia (CBT-I) to see if it helps adults with mild traumatic brain injury sleep better and improve daily functioning.
-
Passive neurosensory reintegration training to help recovery after mild traumatic brain injury
We will try a gentle multisensory therapy called passive neurosensory reintegration training (PNRT) to see if it helps adults with sub-acute or chronic mild traumatic brain injury recover neurosensory and cognitive symptoms.
-
Early Intervention for Adults with Ongoing Post-Concussion Symptoms after Mild TBI
This study tests a package of physical/occupational therapy and telephonic psychoeducation to help adults recover after a mild traumatic brain injury.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.